Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1062-1066

  Nomura, M ^a   Kamata, M ^a   Kojima, H ^a   Hayashi, K ^a   Sawada, S ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Chemotherapy; Irsogladine maleate; Oral mucositis

Indexed keywords

CISPLATIN; FLUOROURACIL; IRSOGLADINE MALEATE; NARCOTIC ANALGESIC AGENT; NEDAPLATIN; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PAIN; CANCER STAGING; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; UTERINE CERVIX CANCER; VOMITING;

EID: 84875588619     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds584     Document Type: Article

References (20)

1. Hiraishi H, Haruma K, Miwa H et al. Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection-the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). Aliment Pharmacol Ther 2010; 3: 824-833.
2. Nanke Y, Kamatani N, Okamoto T et al. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: an open-label, single-centre study. Drugs R D 2008; 9: 455-459.
3. Yoshida T, Hirakata M. Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis. J Rheumatol 2003; 30: 2082-2083.
4. Kyoi T, Noda K, Oka M et al. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci 2004; 76: 71-83.
5. Kyoi T, Oka M, Noda K et al. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci 2004; 75: 1833-1842.
6. Kyoi T, Kitazawa S, Tajima K et al. Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats. J Pharmacol Sci 2004; 95: 321-328.
7. Fujita T, Ashikaga A, Shiba H et al. Irsogladine maleate counters the interleukin-1 beta-induced suppression in gap-junctional intercellular communication but does not affect the interleukin-1 beta-induced zonula occludens protein-1 levels in human gingival epithelial cells. J Periodontal Res 2008; 43: 96-102.
8. Uchida Y, Shiba H, Komatsuzawa H et al. Irsogladine maleate influences the response of gap junctional intercellular communication and IL-8 of human gingival epithelial cells following periodontopathogenic bacterial challenge. Biochem Biophys Res Commun 2005; 333: 502-507.
9. Hara A, Murata H, Uemura R et al. Identification of connexins in human oral mucosa and therapeutic effect of irsogladine maleate on aphthous stomatitis. J Gastroenterol 1999; 34: 1-6.
10. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
11. Stiff PJ, Erder H, Bensinger WI et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006; 37: 393-401.
12. No Author. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301-308.
13. No Author. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16: 3537-3541.
14. Keefe DM, Schubert MM, Elting LS et al. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831.
15. Rosen LS, Abdi E, Davis ID et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracilbased chemotherapy. J Clin Oncol 2006; 24: 5194-5200.
16. Le QT, Kim HE, Schneider CJ et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29: 2808-2814.
17. Henke M, Alfonsi M, Foa P et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29: 2815-2820.
18. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007; 5: 3-11.
19. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003; 39: 91-100.
20. Fuwa N, Kodaira T, Kamata M et al. Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and recommended dose of NDP administered after 5-FU. Am J Clin Oncol 2002; 25: 565-569.